We have discussed today some of the aspects of the desirability or otherwise of treating hypertension and we have heard evidence that patient acceptability is important. This has probably improved with beta-blocking drugs as a group. Acceptability and compliance are likely to be better if the drug is given as infrequently as possible. Originally, hypotensive drugs were given four times a day, then three times, then twice, and now once a day use is being discussed. Together with Dr John Cruickshank of ICI we have been looking into the possibilities of giving atenolol once a day. Besterman (1976) and Kendall & Yates (1976) recently reported escape from f-blockade at 24 hours on metoprolol and acebutolol in studies based on only one dose in otherwise untreated patients. On the other hand, Cruickshank & Douglas-Jones (1976) reported favourably on once daily dosage of atenolol in general practice. We therefore thought it appropriate to study atenolol both after a single administration and also following a period of chronic administration, to reproduce more accurately the effects of the drug in clinical practice.
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Trial Design
The objectives were (1) To study the effect on the resting pulse and blood pressure and postexercise pulse and blood pressure, and (2) To discover if there was any correlation of the effects seen with the serum concentrations of the drug. The entire investigation was to be repeated after a period of chronic, once a day administration, to ascertain whether there was better pulse and blood pressure control and whether the drug was likely to be useful in the treatment of hypertension. The study was designed as shown in Fig 1, in order to obtain good data on what was happening to the pulse and blood pressure during the complete 24-hour period, both resting, and after a standardized exercise test. The patients, who all knew the doctors involved from outpatients, were admitted at about 0800, and allowed one hour or so to settle in. There was a run-in period between 0900 and 1 100 and at 1 100 the first tablet was given, followed two hours later by the second. At least one of these tablets was an identical placebo. The reason why two tablets were used was to avoid any possibility of an acute placebo effect, and in the event no such effect was observed. The resting pulse and blood pressure were taken at half-hourly intervals, using a Roche Arteriosonde 1217 ultrasonic blood pressure monitor, and then at hourly intervals throughout the night until 1100 the following day. Exercise pulse and blood pressure readings were carried out using a standard 2 x 9 in step test, initially worked out with each patient to raise the pulse rate to 120 beats/minute when on no treatment, and maintained at the same individual level on each occasion indicated. Blood was taken for estimation of atenolol levels at the beginning and at 21, 4j and 24 hours.
Five patients were studied for three 26-hour periods each with their informed consent. The first day, called the 'Placebo' day, when both tablets 1 and 2 were placebo, was to find out what happened to the patients' blood pressures when they were simply admitted to hospital and wandered gently around the ward. It was felt there was quite a considerable chance that their blood pressures would fall if that was all that was done, and something objective was needed to compare with active treatment. On day 2, called the 'Acute study', tablets 1 and 2, given in randomized order, were placebo or 100 mg atenolol. The patients were then sent home for 4 weeks and asked to take 100 mg atenolol at about 1100 daily. They were seen at least once in that 4-week period, and as we knew them fairly well, their compliance was extremely good. They were then brought back to hospital for a third study called the 'Chronic study' which was exactly the same as the acute study, but followed the previous one month of regular oral treatment. Fig 2 shows what happened to the resting pulse rates and blood pressures. There was really very little change in either of these parameters over the 24-hour 'Placebo' period. In the 'Acute' study there was a rapid onset of fall in both systolic and diastolic blood pressures and pulse rates, and these were maintained fairly well throughout the 24-hour period. The peak serum levels of atenolol and the half-lives are in agreement with previously published results. (These data are from only three of the five patients. The other two are awaiting analysis.) After one month's chronic treatment the peak levels and half-lives were once more within limits acceptable as normal for the drug, with again a fairly rapid dip in the systolic blood pressure, and a smaller one in the diastolic.
Results
These levels were both considerably lower than on the first administration of the drug, and the pulse rates had also come down a little further.
The post-exercise pulse and blood pressures indicate that the exercise test, designed to get the pulse rate up to 1 20/min on the first occasion was about right (Fig 3) . There diastolic blood pressures. In the acute study most of the effect in terms of reduction of systolic blood pressure was seen by 24 hours with some reduction in diastolic and in pulse rate, and although quite a lot of the effect had worn off by 24 hours after a single administration, there was still considerable decrease in the rise in systolic blood pressure with exercise. After the period of chronic dosing there was an additional effect, with a further lowering of systolic blood pressure after exercise coinciding with the peak levels of the drug in blood, arid a slight drop in pulse rate.
In this part of the study the effects were the same at the end of the 24-hour period as they were in the beginning, with only a slight drop, coinciding with peak levels of the drug, so the effect is maintained throughout the entire 24-hour period. Examination of the degree of beta blockade, based on the inhibition of exercise tachycardia, showed that at 44 hours post-dose there was maximum inhibition which was taken as 100%. Using this as a reference point, 60% inhibition was still present at 24 hours. Using inhibition of exercise systolic hypertension as the criterion of beta blockade, there is about 50% remaining after 24 hours. Table 1 summarizes the mean pulse rates and blood pressuires taken between 24 and 24 hours on each day, when the drug had had time to exert its effect. The resting blood pressure dropped to 157/102 mmHg and after a month's chronic dosing there was a further decrease in pulse rate and in systolic and diastolic blood pressures. The same pattern was seen in the pulse rates and blood pressures following exercise. Summary There were reductions in resting pulse rates and blood pressures after administration of one 100 mg tablet of atenolol, and most of the effect was still present at 24 hours. After chronic administration there were further reductions.
The serum levels peaked at about 21 hours and the plasma half-life was calculated at 8-9 hours, which is what has been found previously. Using inhibition of exercise tachycardia as evidence of beta blockade it was found that there was rapid onset of action, maximal at 41 hours, with 60% of the effect still present at 24 hours. The biological half-life, if it can be expressed in such terms, is therefore some 25 or 26 hours. After ehronic administration, greater inhibition of cxercise tachycardia and hypertension were seen, and these were maintained throughout the 24hour period.
In conclusion, investigation of the effects of atenolol, 100 mg, after chronic once a day oral administration, suggests that this drug is likely to be useful in the treatment of hypertension.
